CN Patent

CN106008639B — 用于预防或治疗fxr-介导疾病的胆烷酸化合物

Assigned to Shenzhen Targetrx Inc · Expires 2019-01-08 · 7y expired

What this patent protects

本发明涉及了一种用于预防或治疗FXR‑介导疾病的胆烷酸化合物。具体地，该发明公开了式（I）所示的胆烷酸化合物以及含有该化合物、或其晶型、药学上可接受的盐、前药、互变异构体和立体异构体、对映异构体、水合物或溶剂合物的药物组合物。本发明所述化合物可作为法尼醇X受体激动剂，进而可适用于制备治疗FXR相关疾病（如脂肪肝等）的药物。

USPTO Abstract

本发明涉及了一种用于预防或治疗FXR‑介导疾病的胆烷酸化合物。具体地，该发明公开了式（I）所示的胆烷酸化合物以及含有该化合物、或其晶型、药学上可接受的盐、前药、互变异构体和立体异构体、对映异构体、水合物或溶剂合物的药物组合物。本发明所述化合物可作为法尼醇X受体激动剂，进而可适用于制备治疗FXR相关疾病（如脂肪肝等）的药物。

Drugs covered by this patent

Patent Metadata

Patent number
CN106008639B
Jurisdiction
CN
Classification
—
Expires
2019-01-08
Drug substance claim
No
Drug product claim
No
Assignee
Shenzhen Targetrx Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.